Agenus (NASDAQ:AGEN) Upgraded at Wall Street Zen

Agenus (NASDAQ:AGEN) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Agenus in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Agenus presently has an average rating of “Hold” and an average target price of $14.50.

Agenus Price Performance

Shares of NASDAQ AGEN opened at $3.71 on Friday. The stock’s fifty day moving average price is $3.26 and its two-hundred day moving average price is $3.76. Agenus has a one year low of $1.38 and a one year high of $7.34. The firm has a market cap of $142.46 million, a price-to-earnings ratio of -8.07 and a beta of 1.57.

Agenus (NASDAQ:AGEN) last posted its earnings results on Monday, March 16th. The biotechnology company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.27) by $1.83. Agenus had a negative return on equity of 7.65% and a negative net margin of 2.67%.The company had revenue of $34.20 million during the quarter, compared to the consensus estimate of $28.10 million. On average, equities analysts anticipate that Agenus will post -12.55 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Agenus

Several institutional investors and hedge funds have recently bought and sold shares of AGEN. Renaissance Technologies LLC lifted its position in shares of Agenus by 721.1% during the 4th quarter. Renaissance Technologies LLC now owns 543,546 shares of the biotechnology company’s stock worth $1,707,000 after buying an additional 477,346 shares during the last quarter. Marshall Wace LLP bought a new position in Agenus in the second quarter valued at about $1,976,000. AQR Capital Management LLC grew its position in Agenus by 3,080.3% in the first quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock valued at $664,000 after acquiring an additional 427,604 shares during the last quarter. Bank of America Corp DE raised its stake in Agenus by 110.0% during the second quarter. Bank of America Corp DE now owns 420,678 shares of the biotechnology company’s stock worth $1,922,000 after acquiring an additional 220,327 shares in the last quarter. Finally, Walleye Capital LLC acquired a new position in Agenus during the second quarter worth about $906,000. Institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.